Spots Global Cancer Trial Database for telisotuzumab vedotin
Every month we try and update this database with for telisotuzumab vedotin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | NCT05513703 | Non Small Cell ... | Telisotuzumab V... | 18 Years - | AbbVie | |
| A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors | NCT02099058 | Advanced Solid ... | Osimertinib Nivolumab Telisotuzumab v... Telisotuzumab v... Erlotinib | 18 Years - | AbbVie | |
| A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | NCT04928846 | Non Small Cell ... | Telisotuzumab V... Docetaxel | 18 Years - | AbbVie | |
| Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein | NCT06093503 | Non-Small Cell ... | Telisotuzumab V... Osimertinib Cisplatin Carboplatin Pemetrexed | 18 Years - | AbbVie | |
| A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | NCT04928846 | Non Small Cell ... | Telisotuzumab V... Docetaxel | 18 Years - | AbbVie | |
| Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | NCT03539536 | Non-small Cell ... | Telisotuzumab v... | 18 Years - | AbbVie | |
| A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors | NCT02099058 | Advanced Solid ... | Osimertinib Nivolumab Telisotuzumab v... Telisotuzumab v... Erlotinib | 18 Years - | AbbVie | |
| A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | NCT05513703 | Non Small Cell ... | Telisotuzumab V... | 18 Years - | AbbVie | |
| Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | NCT03539536 | Non-small Cell ... | Telisotuzumab v... | 18 Years - | AbbVie | |
| A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | NCT04928846 | Non Small Cell ... | Telisotuzumab V... Docetaxel | 18 Years - | AbbVie |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
